Lantheus Holdings, Inc. Announces Departure of Chief Medical Officer

Lantheus Holdings, Inc. (NASDAQ: LNTH) recently disclosed in an 8-K filing with the Securities and Exchange Commission that Jeff Humphrey, MD, will no longer serve as the Chief Medical Officer of the company. His last day of employment with Lantheus Holdings, Inc. is scheduled for January 3, 2025.

The departure of Dr. Humphrey was clarified in the filing to not be a result of any disagreement with the company, its Board, or management regarding its operations, clinical programs, policies, or practices. Lantheus Holdings, Inc. disclosed that a search is currently in progress to identify a suitable candidate for Dr. Humphrey’s replacement.

During this interim period, Brian Markison, CEO, and Paul Blanchfield, President, have taken on additional responsibilities in leading the research and development endeavors of the company.

Lantheus Holdings, Inc. registered this disclosure as per Item 7.01 of Regulation FD (Fair Disclosure) with the SEC on December 19, 2024. The company, whose common stock trades on The Nasdaq Global Market under the symbol “LNTH,” confirmed the departure of its Chief Medical Officer through this filing.

The company’s Chief Administrative Officer and General Counsel, Daniel Niedzwiecki, signed off on the filing on behalf of Lantheus Holdings, Inc. on December 19, 2024.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Lantheus’s 8K filing here.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.